RE:RE:RE:The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won'tExpansion of Big Pharma's "sweet spot " to US $25 Billion falls in line with the perspective that the FTC will likely not review any M&A deal under US$ 23 Billion, as commented on before.
This places ONCY in a good position in having the company valued and acquired between $10 - $15 Billion.